LOGIN  |  REGISTER

Eiger BioPharmaceuticals (NASDAQ: EIGR) Stock Quote

Last Trade: US$5.01 0.02 0.40
Volume: 3,946
5-Day Change: -6.89%
YTD Change: 2,172.73%
Market Cap: US$7.410M

Latest News From Eiger BioPharmaceuticals

Clinical trial data demonstrated Zokinvy treatment extended life by an average of 4.3 years in children and young adults with Hutchinson-Gilford progeria Eiger to receive $500,000 approval milestone payment from AnGes Zokinvy approved in the U.S. (2020), 30 European countries (2022), and now Japan (2024) PALO ALTO, Calif. , Jan. 18, 2024 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage... Read More
PALO ALTO, Calif. , Jan. 4, 2024 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR) (the "Company"), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare metabolic diseases, today announced that it will conduct a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-30 (the "Reverse Stock Split"). The Reverse Stock Split will become... Read More
Resources prioritized to advance avexitide in hyperinsulinemic hypoglycemia indications Phase 3 LIMT-2 study of peginterferon lambda in chronic hepatitis delta discontinued due to safety findings Company's cash runway expected to extend into the third quarter of 2024 PALO ALTO, Calif. , Nov. 9, 2023 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the... Read More
PALO ALTO, Calif. , Sept. 12, 2023 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare metabolic diseases, today announced its decision to discontinue the Phase 3 LIMT-2 study of peginterferon lambda in patients with chronic hepatitis delta (CHD). The decision is based on the recommendation of the Data Safety... Read More
PALO ALTO, Calif. , Sept. 5, 2023 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare metabolic diseases, today announced that David Apelian , MD, PhD, MBA, CEO of Eiger, will present a company overview at the H.C. Wainwright 25 th Annual Global Investment Conference on Monday, September 11, 2023 at 7:00 AM ET... Read More
Resources prioritized to advance avexitide in hyperinsulinemic hypoglycemia indications Active discussions underway with potential partners to advance late-stage virology programs Reduction in workforce executed to align with focus on avexitide; extends cash runway into Q4 2024 David Apelian , MD, PhD, MBA, appointed CEO PALO ALTO, Calif. , Aug. 14, 2023 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a... Read More
Prioritizing resources to advance avexitide in hyperinsulinemic hypoglycemia indications Active discussions underway with potential partners to advance late-stage virology programs Reduction in workforce executed to align with focus on avexitide; extends cash runway to Q4 2024 David Apelian , MD, PhD, MBA, appointed CEO Live conference call and webcast at 8:30 am ET today PALO ALTO, Calif. , June 29, 2023 /PRNewswire/ --... Read More
Company to host conference call and live webcast on Thursday, June 29 , at 8:30 am ET PALO ALTO, Calif. , June 28, 2023 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for rare diseases, today announced that following an extensive portfolio prioritization exercise, the company will host a conference call and live... Read More
Phase 3 HDV D-LIVR (lonafarnib/ritonavir) Study: Pre-NDA Meeting with FDA in Q2 Phase 3 HDV LIMT-2 (peginterferon lambda) Study: Complete Randomization in Q2 Phase 3 HI AVANT (avexitide) Program: Startup Activities Initiated Cash Position: $75.3 million in Cash, Cash Equivalents, and Short-Term Debt Securities as of March 31, 2023 PALO ALTO, Calif. , May 11, 2023 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc . (Nasdaq:EIGR),... Read More
PALO ALTO, Calif. , May 3, 2023 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases, today reported that, in connection with the appointment of James A. Vollins as General Counsel, Chief Compliance Officer and Corporate Secretary, Eiger granted him a stock... Read More
William G. Kachioff appointed as Chief Financial Officer James A. Vollins appointed as General Counsel, Chief Compliance Officer and Corporate Secretary PALO ALTO, Calif. , April 13, 2023 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases, today announced the... Read More
Phase 3 HDV D-LIVR (lonafarnib/ritonavir) Study: Pre-NDA Meeting Planned by End of Q2 Phase 3 HDV LIMT-2 (peginterferon lambda) Study: On Track to Complete Randomization by End of Q2 Phase 3 HI AVANT (avexitide) Program: Startup Activities Initiated Cash Position: $98.9 million in Cash, Cash Equivalents, and Short-Term Debt Securities as of December 31, 2022 PALO ALTO, Calif. , March 16, 2023 /PRNewswire/ -- Eiger... Read More
Phase 3 TOGETHER data showed early treatment with a single dose of peginterferon lambda (Lambda) in patients with mild-to-moderate COVID-19 infections resulted in significantly decreased clinical events Lambda reduced risk of hospitalization or emergency room visits by 51% (primary endpoint) Lambda reduced risk of hospitalization by 42% and COVID-19 related death by 50% Effects consistent across multiple dominant SARS-CoV-2... Read More
Lonafarnib/ritonavir response rate of 10.1% (p=0.0044) Lonafarnib/ritonavir in combination with peginterferon alfa response rate of 19.2% (p<0.0001) Peginterferon alfa comparator arm, included for contribution of effect, response rate of 9.6% Key secondary endpoint of proportion of patients with improvement in histological response rate demonstrated with statistical significance in combination arm vs placebo PALO ALTO,... Read More
Live Conference Call and Webcast at 8:30 AM ET PALO ALTO, Calif. , Dec. 7, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus (HDV) and other serious diseases, today announced that it will host a conference call on Thursday, December 8, 2022, at 8:30 AM Eastern Time, to discuss the... Read More
Surmodics

COPYRIGHT ©2023 HEALTH STOCKS HUB